Neochromosome and GlobalBio Launch Pre-Transformed Antibody Libraries in Switchable Yeast Platform

Article content

GlobalBio’s validated, highly diverse human antibody libraries are now available pre-integrated into Neochromosome’s novel neoSwitch™ yeast strain, enabling rapid in-house antibody discovery via yeast display and streamlined lead characterization in secretion mode.

Article content

LONG ISLAND CITY, N.Y. & CAMBRIDGE, Mass. — Neochromosome, Inc., the genome-scale cell engineering subsidiary of lab automation leader, Opentrons Labworks, today announced a turnkey solution for in-house biologics discovery. The platform integrates GlobalBio, Inc.’s clinically validated antibody libraries into the Neochromosome^® neoSwitch™ yeast strain—a novel system that can both surface-display and secrete VHHs, scFvs, and other proteins relevant to therapeutics discovery. This approach enables rapid hit identification and lead optimization, saving weeks per iteration and cutting months from traditional discovery timelines.

Article content

Article content

Article content

The partnership addresses the cost, complexity, and long timelines typically associated with therapeutic antibody screening. GlobalBio’s ALTHEA Libraries™ contain billions of scFv and VHH candidates, with multiple leads already validated in clinical programs. By combining these libraries with the Neochromosome neoSwitch™ platform, organizations can run rapid in-house screening campaigns with seamless transitions from discovery to soluble antibody production. Biotechnology and pharmaceutical companies can reduce costs by an order of magnitude, identify lead candidates in as little as four weeks and move straight into characterization.

Article content

Article content

“This partnership resolves a long-standing challenge in biologics discovery: the tradeoffs between cost, quality, and speed,” said Leslie Mitchell, PhD, CSO of Opentrons. “For years, companies have had to choose between working with opaque and unpredictable CROs, building internal capabilities over multiple years, or paying steep access fees for proprietary platforms. We’re removing that choice entirely. With a target antigen in hand, researchers can start screening immediately and identify high-quality leads in just weeks – at a fraction of the traditional cost.”

Article content

The global biologics market – projected to exceed $700 billion by 2030 – is fueled largely by the success of monoclonal antibody (mAb) therapeutics across oncology, immunology, and infectious disease. As the field has matured, demand is rising for alternative formats that leverage antibody fragments or domains as modular targeting components in the research and development of next-generation therapies such as:

Article content

Article content

Yet access to high-quality yeast-display antibody libraries remains a major bottleneck. Traditional approaches depend on animal immunization or de novo synthetic library construction—processes that can take months, cost millions, and remain out of reach for many organizations.

Article content

“The entire industry has been trying to accelerate discovery while relying on fundamentally slow processes,” said Juan Carlos Almagro, PhD, CEO of GlobalBio and former head of antibody design at Johnson & Johnson. “Our ALTHEA Libraries™ contain therapeutic candidates with proven clinical potential, derisking biologics screening. Neochromosome’s platform, powered by Opentrons Flex automated workflows, is helping remove months and millions of dollars from the process entirely.”

Article content

Article content

The partnership’s impact lies in solving multiple technical challenges that have long stifled antibody discovery:

Article content

Pre-Transformation at Scale

Article content

:

Article content

Article content

Libraries containing billions of unique antibodies come pre-loaded into switchable yeast, eliminating the 2-3 months of prep work often required to initiate a discovery campaign.

Article content

Seamless Mode Switching

Article content

:

Article content

Article content

The neoSwitch platform enables straightforward transitions from surface display (for binder selection) to secretion (for soluble lead production) via simple media changes with no subcloning and no host switching. What traditionally required weeks now happens in hours.

Article content

Proven Performance of GlobalBio’s ALTHEA libraries

Article content

™:

Article content

Article content

“Antibody discovery lacks true end-to-end solutions. The Neochromsome neoSwitch strain solves a major pain point by making yeast display plug-and-play. Their partnership with GlobalBio delivers a powerful combined library and screening platform for VHH and scFv discovery from high-diversity libraries. It’s an ideal solution for teams rapidly screening candidates by flow, binning, or for affinity optimization” said Dr. William Strohl, former Head of Biologics at Johnson & Johnson and author of Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry

Article content

The partnership offers flexible access models to meet the needs of organizations of all sizes:

Article content

Article content

Pharmaceutical companies often maintain long lists of promising therapeutic targets that were shelved due to prohibitive discovery timelines or costs. By reducing both time and expense by over 90%, this platform makes many of those programs viable again.